Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
1. MURA halted the ARTISTRY-7 trial due to poor efficacy results. 2. The combination treatment did not improve overall survival compared to chemotherapy. 3. Stock dropped 49.6% in premarket trading following the announcement. 4. Nemvaleukin has a good safety profile but is not viable for current indications. 5. Next data readouts for nemvaleukin expected in 2025 for other melanoma types.